Group 1 - The company, Zhonghui Biotech-B, plans to conduct an IPO from July 31 to August 5, 2025, aiming to globally offer 33.4426 million H-shares at a price range of HKD 12.9 to HKD 15.5 per share [1] - Zhonghui Biotech is a Chinese vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines, with a product pipeline that includes a quadrivalent influenza virus subunit vaccine and a lyophilized human rabies vaccine [1] - The company has signed cornerstone investment agreements with Jiaxing Xinyang and Huatai Capital Investment, with cornerstone investors set to subscribe for shares worth USD 13 million [1] Group 2 - The net proceeds from the offering are expected to be HKD 421 million, which will primarily be used for core product development, development of other vaccines in the pipeline, enhancement of production and commercialization capabilities, and development of technology platforms [1]
中慧生物-B招股 拟全球发售3344.26万股H股
Zheng Quan Shi Bao Wang·2025-07-31 01:25